By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Aduro Biotech 

740 Heinz Avenue

Berkeley  California  94710  U.S.A.
Phone: 510-848-4400 Fax: n/a


Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro's technology platforms, which are designed to harness the body's natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases. Aduro's LADD technology platform is based on proprietary attenuated strains of Listeria that have been engineered to express tumor-associated antigens to induce specific and targeted immune responses. This platform is being developed as a treatment for multiple indications, including pancreatic, ovarian, lung and prostate cancers, mesothelioma and glioblastoma. Aduro's STING Pathway Activator platform is designed to activate the intracellular STING receptor, resulting in a potent tumor-specific immune response. ADU-S100 is the first STING Pathway Activator compound to enter the clinic and is currently being evaluated in a Phase 1 study in patients with cutaneously accessible metastatic solid tumors or lymphomas. Aduro’s B-select monoclonal antibody platform includes a number of immune modulating assets in research and preclinical development. Aduro is collaborating with leading global pharmaceutical companies to expand its products and technology platforms.

Key Statistics

Ownership: Public

Web Site: Aduro Biotech
Symbol: ADRO



Company News
HitGen And Aduro Biotech (ADRO) Enter Research Collaboration 8/14/2017 11:02:22 AM
Aduro Biotech (ADRO) Bolsters Intellectual Property Position In STING Field With Two New Patents 8/9/2017 10:40:05 AM
Aduro Biotech (ADRO) Reports Second Quarter 2017 Financial Results 8/3/2017 1:45:40 PM
Aduro Biotech (ADRO) Announces Andrea Van Elsas, Ph.D., To Be Named Chief Scientific Officer Effective September 1, 2017 7/27/2017 10:35:53 AM
Aduro Biotech (ADRO) Announces Milestone Achieved Relating To Collaboration With Merck & Co. (MRK) For Development Of Anti-CD27 Antibody For The Treatment Of Cancer 7/13/2017 8:14:36 AM
Aduro Biotech (ADRO) Announces First Patient Dosed In Phase II Clinical Trial Of CRS-207 In Combination With KEYTRUDA® (Pembrolizumab) For The Treatment Of Patients With Previously Treated Malignant Pleural Mesothelioma 6/29/2017 10:33:19 AM
Aduro Biotech (ADRO) Announces FDA Clearance Of Investigational New Drug Application To Evaluate The Combination Of ADU-S100 With PDR001 For The Treatment Of Solid Tumors And Lymphomas 6/1/2017 10:31:28 AM
Aduro Biotech (ADRO) Announces Clinical Collaboration With Merck & Co. (MRK) To Evaluate The Combination Of Aduro’s CRS-207 With Merck's KEYTRUDA (Pembrolizumab) For The Treatment Of Mesothelioma 5/17/2017 10:48:21 AM
Aduro Biotech (ADRO) Reports First Quarter 2017 Financial Results 5/3/2017 10:44:36 AM
Aduro Biotech (ADRO) Announces Management Promotions 4/21/2017 10:58:49 AM